Results of a randomized, placebo-controlled, double-blind, parallel-group 4-week study of pediatric patients 6 to <12 years of age with moderate-to-severe symptomatic PAR (n=161 for patients receiving azelastine HCl 0.15% solution, and n=162 for patients receiving placebo). Primary endpoint was change from baseline in 12-hour combined AM + PM reflective TNSS.5